Tags

Type your tag names separated by a space and hit enter

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Expert Rev Neurother 2012; 12(4 Suppl):3-8ER

Abstract

Multiple sclerosis (MS) is associated with a wide range of disease symptoms and amongst these, spasticity is one of the most disabling and has the greatest impact on patient well-being and quality of life. Until now, available drug therapies for spasticity appear to have limited benefit and are often associated with poor tolerability. In a recent Spanish survey it was noted that multidrug therapy and a low control rate were common features for a large proportion of patients with MS-related spasticity, suggesting that currently available monotherapies lack significant activity. Sativex is a 1:1 mixture of δ-9-tetrahydrocannabinol and cannabidiol derived from Cannabis sativa chemovars, which is available as an oromucosal spray. Clinical experience with Sativex in patients with MS-related spasticity is steadily accumulating. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status. These are highly encouraging findings that provide some much needed optimism for the treatment of this disabling and often painful symptom of MS.

Authors+Show Affiliations

Department of Neurology, Neuroimmunology and Multiple Sclerosis Unit, Health Research Institute (IdiPAZ), University Hospital La Paz/Autónoma University of Madrid, Madrid, Spain. orejacbn@gmail.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22509985

Citation

Oreja-Guevara, Celia. "Clinical Efficacy and Effectiveness of Sativex, a Combined Cannabinoid Medicine, in Multiple Sclerosis-related Spasticity." Expert Review of Neurotherapeutics, vol. 12, no. 4 Suppl, 2012, pp. 3-8.
Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother. 2012;12(4 Suppl):3-8.
Oreja-Guevara, C. (2012). Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Review of Neurotherapeutics, 12(4 Suppl), pp. 3-8. doi:10.1586/ern.12.11.
Oreja-Guevara C. Clinical Efficacy and Effectiveness of Sativex, a Combined Cannabinoid Medicine, in Multiple Sclerosis-related Spasticity. Expert Rev Neurother. 2012;12(4 Suppl):3-8. PubMed PMID: 22509985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. A1 - Oreja-Guevara,Celia, PY - 2012/4/19/entrez PY - 2012/4/25/pubmed PY - 2012/8/11/medline SP - 3 EP - 8 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 12 IS - 4 Suppl N2 - Multiple sclerosis (MS) is associated with a wide range of disease symptoms and amongst these, spasticity is one of the most disabling and has the greatest impact on patient well-being and quality of life. Until now, available drug therapies for spasticity appear to have limited benefit and are often associated with poor tolerability. In a recent Spanish survey it was noted that multidrug therapy and a low control rate were common features for a large proportion of patients with MS-related spasticity, suggesting that currently available monotherapies lack significant activity. Sativex is a 1:1 mixture of δ-9-tetrahydrocannabinol and cannabidiol derived from Cannabis sativa chemovars, which is available as an oromucosal spray. Clinical experience with Sativex in patients with MS-related spasticity is steadily accumulating. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status. These are highly encouraging findings that provide some much needed optimism for the treatment of this disabling and often painful symptom of MS. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/22509985/Clinical_efficacy_and_effectiveness_of_Sativex_a_combined_cannabinoid_medicine_in_multiple_sclerosis_related_spasticity_ L2 - http://www.tandfonline.com/doi/full/10.1586/ern.12.11 DB - PRIME DP - Unbound Medicine ER -